The addition of ABS scientists and resources establishes UBC with the presence and operational reach in the New England biomedical corridor and adds to its portfolio of scientific and medical affairs solutions to support biopharmaceutical and medical technology companies.
With the acquisition, UBC further expands its team of senior experts in comparative effectiveness and comparative value, increases its registry and observational study practices, and reinforces its commercial strategy and market access capabilities.
Kathleen Flanagan, associates president and chief executive officer of Abt, said: “After building ABS into a respected player in its field, we are gratified to see our colleagues join a company that shares our values and can realize even greater potential. At UBC, there will be new resources and increased reach that translates into new opportunities for our clients to support their products.”
Ethan Leder, CEO of UBC, said: “The scientists and capabilities that we gain with ABS are an excellent fit with our strategy.”
Based in Lexington, Massachusetts, ABS provides health economics and outcomes research, registries and observational studies, and market access solutions to the medical device, and diagnostics industries.
